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Background: Global noise in gene expression and chromosome duplication during cell-cycle progression cause
inevitable fluctuations in the effective number of copies of gene networks in cells. These indirect and direct
alterations of network copy numbers have the potential to change the output or activity of a gene network. For
networks whose specific activity levels are crucial for optimally maintaining cellular functions, cells need to
implement mechanisms to robustly compensate the effects of network dosage fluctuations.
Results: Here, we determine the necessary conditions for generalized N-component gene networks to be
network-dosage compensated and show that the compensation mechanism can robustly operate over large ranges
of gene expression levels. Furthermore, we show that the conditions that are necessary for network-dosage
compensation are also sufficient. Finally, using genome-wide protein-DNA and protein-protein interaction data, we
search the yeast genome for the abundance of specific dosage-compensation motifs and show that a substantial
percentage of the natural networks identified contain at least one dosage-compensation motif.
Conclusions: Our results strengthen the hypothesis that the special network topologies that are necessary for
network-dosage compensation may be recurrent network motifs in eukaryotic genomes and therefore may be an
important design principle in gene network assembly in cells.
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The effective dosage of a gene network – the number of
network copies in a cell – can vary significantly both
throughout a cell’s lifetime and across different cells in
the same clonal population. Such changes can arise from
a variety of direct and indirect causes. For example,
DNA replication during the cell cycle [1] would double
the network dosage, and it has been shown that many
promoters indeed display an increase in transcription
consistent with gene dosage effects during the G2 phase
of the cell cycle as compared to G1 [2]. Similarly, organisms
such as yeast that switch between haploid and diploid life* Correspondence: murat.acar@yale.edu
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unless otherwise stated.forms [3] must cope with the increased network dosage.
Global noise in gene expression [4,5] could also lead to sig-
nificant variations in effective network dosage. Moreover,
such changes can have significant effects on the cellular
phenotypes [6]. For example, in multicellular organisms,
widespread dosage changes can be fatal [7]. It stands to rea-
son, therefore, that cells must have evolved mechanisms to
compensate for such dosage alterations, including the
inevitable alterations occurring at the gene network
level. Despite the presence of previous studies [8,9] fo-
cusing on dosage variations of individual genes, there
is very little work [10] approaching this question from
the gene network point of view. Due to the presence of
nonlinear feedback interactions among the individual
genes of a gene network, dosage compensation analyses
focusing on individual genes one at a time cannot reliably
predict whether or not the activity of their network would
be compensated.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ose signaling pathway (GAL pathway) in Saccharomyces
cerevisiae is dosage compensated on the network level: the
activity of the network showed no significant change when
the dosage of the entire regulatory network was halved in
diploid cells. By mathematically and computationally ana-
lyzing 2-component networks, the study further demon-
strated that such compensation effect could arise solely as
a feature of the structure of the gene network. Outside of
a trivial case, 1-component networks could not be dosage
invariant, but 2-component networks could be if they
satisfied certain criteria: the two components had to have
different regulatory signs, they had to interact with a 1:1
stoichiometry, and the effects of one of the two compo-
nents had to be indirect and exerted its effects on tran-
scription through action on the other component [10].
The questions remain, however, regarding how the
network-dosage compensation analysis can be extended
to N-component networks, whether the compensation
mechanism can robustly operate over broad gene ex-
pression ranges, and finally whether the specific dosage-
compensation topologies are recurrent network motifs
in natural gene networks. In this study, we first expand
the mathematical compensation analysis beyond the 1-
component and 2-component networks, so that the ana-
lysis includes gene networks of any size (N-component
networks), demonstrating that a necessary condition for
dosage compensation in such networks is the existence
of a 2-component subnetwork with an activator and an
inhibitor. We then perform a network-dosage compensa-
tion analysis on 2-component networks and show that the
compensation mechanism acts over large gene expression
and protein degradation ranges, not just the specific levels
displayed by the GAL network components. Furthermore,
we show that the conditions that are necessary for an
inducible network to be network-dosage compensated
are also sufficient. Finally, using genome-wide protein-
DNA and protein-protein interaction data, we search
the S. cerevisiae genome for the abundance of the spe-
cial network topologies necessary for network-dosage
compensation, and show that a substantial percentage
of the natural networks identified contain at least one
dosage-compensation topology.
Results
Mathematical analysis of network-dosage compensation
in N-component gene networks
To investigate the necessary and sufficient conditions
that can make an N-component gene network dosage-
compensated, we consider a network composed of N genes
that are under the control of the same transcription factor
(TF). In our analysis, we define gene networks as structures
that have varying numbers of genes that are all under the
control of a common TF for each gene network.The network under consideration can be represented
by the following set of differential equations describing
the time evolution of the concentrations of proteins
expressed from the network genes:
dx1
dt








Here, xi represents the average total concentration of
the ith protein, θi represents the maximal expression rate
for the ith gene, γ represents the cell-division rate, ρ rep-
resents an external control parameter with which the
network can be induced, and f(ρ,x1,…,xN) represents the
activity of the gene network or the fraction of active pro-
moter sites. We assume that the network proteins are
diluted at the cell-division rate (γ), corresponding to
cases in which protein lifetimes are much longer than
the cell-division time. We further assume that network
proteins interact with each other on fast timescales and
that these interactions determine the fractional activity
of the transcription center represented by the function f,
whose value is limited to the range [0, 1]. Then, each gene
is expressed proportionally to the activity of the common
transcription center.
With this framework, we are interested in elucidating
the general network features that can keep the activity of
the transcriptional center to be compensated (or invariant)
to parallel changes in the maximal expression rate of
the network genes. Cells would experience such paral-
lel changes due to the effects of global noise in expres-
sion, or when chromosomes are replicated during cell
cycle progression.
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We consider cases in which θ1, θ2, …, θN are propor-
tionally changed by introducing a new parameter:
1þ δð Þθ1 f ρ; x1;…; xNð Þ ¼ γx1
⋮
1þ δð ÞθNf ρ; x1;…; xNð Þ ¼ γxN
8<
: ð3Þ
Taking the derivative of both sides of the first equation
above with respect to δ, we have











From Eq. 2, we have
xm ¼ θm
θ1
x1 for m ¼ 2;…;N








for m ¼ 2;…;N ð5Þ
Plugging this equation into Eq. 4, we obtain an equation
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þ…þ θN ∂f∂xN ¼ 0. As all parameters here are positive
and at least some of the partial derivatives are nonzero, at
least one of the partial derivatives must be positive and at
least one must be negative. Therefore, in order to keep the
activity of an N-component gene network compensated
against parallel changes in the number of network com-
ponents, a necessary condition is that the network has
to be composed of components of different regulatory signs
(e.g. 1 activator and N-1 inhibitors, 2 activators and N-2 in-
hibitors, etc.). In other words, the gene network must have
a 2-component subnetwork with components of different
regulatory signs (i.e., one activator and one inhibitor).
How can certain interaction topologies between net-
work components facilitate the dosage compensation
behavior of the network activity? Will the compensation
mechanism operate for a wide range of gene expression
levels and protein degradation rates, or is it limited to
the specific parameter values used in the previous work
[10], which correspond to the GAL network? 2-component
subnetworks composed of one activator and one inhibi-
tor provide effective minimal systems to address these
questions. In the next section, we numerically analyze
2-component subnetworks to find out whether or not
specific gene expression and protein degradation levels
are required for observing compensated network activity
in gene networks.Sensitivity analysis of the network-dosage compensation
mechanism with respect to the gene expression and
protein degradation levels
To explore if certain 2-component interaction topolo-
gies would make it easier or harder for cells to show
network dosage compensation, we numerically analyzed
2-component topologies in which an activator (a) and an
inhibitor (i) are controlled by a common transcriptional
center and quantified their compensation and inducibil-
ity levels. The specific interaction schemes we analyzed
are depicted in Figure 1B-D. Each interaction topology is
represented by a mathematical form involving four parame-
ters quantifying the scales of action for the activator (Sa)
and inhibitor (Si) and the nonlinearities with which the acti-
vator (α) and inhibitor (β) interacts with their downstream
targets, as follows (Additional file 1: Figure S2):
Topology in Figure 1B:




Topology in Figure 1C:
f g; a; ið Þ ¼ 1
1þ Sii1þ Sagað Þα
 β ð10Þ
Topology in Figure 1D:
f g; a; ið Þ ¼ 1




For each topology, our analysis involved numerically
solving the following differential equations at t = 24 h:
da
dt
¼ Nθa λa 1−f g; a; ið Þð Þ þ f g; a; ið Þ½ −γ0a−γaa
di
dt




In the mathematical form describing f, the parameter
values corresponding to Sa, Si, α and β were sampled
from large ranges as described in Table 1. To verify the
generality of the compensation mechanism beyond the
specific context of the GAL network [10], we chose a
variety of different values for the parameters describing
the maximal transcription/translation activity (θa and θi)
and the rate of protein degradation (γa and γi) (Table 1).
In these equations, γ0 is the cell division rate and λa and
λi quantifies the basal protein expression level. Inserted
into the above coupled differential equation, each set of
the sampled parameters, the chosen parameters, and the
external inducer level (g) corresponded to a new solution
for [a, i]. We used the resulting values for activator and
Figure 1 Network-dosage compensation and specific topologies that are capable or incapable of facilitating network-dosage compensation. A.
Cells having one- or N-copies of a general gene network. Each copy of the network is composed of a master transcription factor (encoded by the first gene,
in green) of the cascade and additional components (blue, red, yellow genes driven by their own promoters carrying binding sites for the common TF). In
turn, the expression levels of the additional network components can affect the activity of the network (purple dashed arrows). The network(s) in each cell is
induced by an input signal. Depending on whether or not the network has the dosage-compensation capability, the two outputs can be similar or different.
B-H. Dosage-compensated and non-compensated network structures. Green squares represent the transcriptional machinery that controls the expression of
the two network components. B-C. Two network structures that are capable of dosage compensation. D. A network structure that is incapable of dosage
compensation. E-H. Four network structures that could not be dosage compensated because the two network components have the same regulatory sign.
Table 1 List of ODE model parameters, their descriptions,
and values
Parameter Description Value
Sa Activator scale of action Logarithmically sampled
from [10−3, 103]
Si Inhibitor scale of action Logarithmically sampled
from [10−4, 102]
α Stoichiometry parameter Linearly sampled from
[0.2, 5]
β Stoichiometry parameter Linearly sampled from
[0.2, 5]
θa Activator production rate 300, 1500 or 7500/hr
θi Inhibitor production rate 300, 1500 or 7500/hr
γ0 Dilution rate constant 0.46/hr
ta Activator half-life 5, 30, 120 or ∞ min
γa Activator degradation rate constant ln(2)/ta
ti Inhibitor half-life 5, 30, 120 or ∞ min
γi Inhibitor degradation rate constant ln(2)/ti
N Network copy number 1 or 2
λa Activator basal production coefficient 0.20
λi Inhibitor basal production coefficient 0.20
g Inducer strength 10-2+0.025C, where
C = 0, 1, 2, …, 80
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curves, defined for each topology by f(g, a, i).
To quantify the degree of compensation in each net-
work topology, we produced separate inducibility curves
with one (N = 1) or two (N = 2) sets of the activator and
inhibitor genes, and computed the area between those
curves. The larger the area between the two curves, the
higher the penalty to compensation in the network
(Additional file 1: Figure S1A). In principle, dosage-
varied networks that cannot be activated beyond their
basal activity levels or networks that always stay ‘ON’
irrespective of the inducer levels can also be classified
as dosage-compensated, but they lack the ability to act
as regulatory networks against external physiological
signals. Therefore, it is also important to determine if a
dosage-compensated network’s inducibility level corre-
sponds to physiologically relevant levels. For this, we
quantified the relative inducibility levels of the numer-
ical inducibility curves against a reference inducibility
curve (Additional file 1: Figure S1B and C), and plotted
them against the compensation levels. Representative plots
for a random sample containing approximately 1.4% of the
networks examined (20,000 networks out of 1,440,000) are
presented in Additional file 1: Figure S2D-F. We found that
only networks with the topologies in Figure 1B and C are
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compensation and inducibility.
To better understand the distribution of parameters
that can give rise to high degrees of compensation and
inducibility, we analyzed the system parameters for all
networks that are both dosage compensated and inducible.
This analysis included examination of the effect of protein
expression levels on the compensation behavior of each
topology by looking at the maximal protein production
rates θ and protein degradation rates γ. To conduct the
compensation analysis at different expression levels, we
selected parameter values for θ and γ from large ranges
that were physiologically relevant (Table 1). As shown
in Figure 2, the different combinations of the values we

















































































Figure 2 The compensation mechanism can operate over large range
showing the number of inducible and dosage compensated networks (N =
combination of protein half-lives. st, stable. B. Bar plots showing the numb
topology of Figure 1B with the specified combination of maximum protein
number of inducible and dosage compensated networks (N = 6124) having
half-lives. st, stable. D. Bar plots showing the number of inducible and dosa
specified combination of maximum protein production rates (in proteins/haffecting the population of data points falling into the
compensated and inducible region of each dot plot
(Additional file 1: Figure S2D-F). In other words, the com-
pensation mechanism can robustly operate over large ex-
pression ranges and it is not limited to the expression
values displayed by the GAL network components.
Analysis of the other parameters to the model demon-
strate that, for each network topology, only the value of
one parameter is strongly constrained in networks that
are both dosage compensated and inducible (Figure 2,
Figure 3A and B, Additional file 1: Figure S3). For both
network topologies, the critical parameter is the parameter
defining the nature of the stoichiometric interaction be-
tween the activator and inhibitor of the 2-component




































































s of protein production and degradation rates. A. Bar plots
6746) having the topology of Figure 1B with the specified
er of inducible and dosage compensated networks having the
production rates (in proteins/hour) θa and θi. C. Bar plots showing the
the topology of Figure 1C with the specified combination of protein
ge compensated networks having the topology of Figure 1C with the
our) θa and θi.
Figure 3 The parameter quantifying the nonlinearity of interaction between the network components is strongly constrained in
dosage-invariant inducible networks. A. Histogram of the value of the sampled parameter β in dosage-invariant inducible networks having the
topology of Figure 1B (green area in Figure S2D, N = 6746). B. Histogram of the value of sampled parameter α in dosage-invariant inducible
networks having the topology of Figure 1C (green area in Figure S2E, N = 6124). C-D. Plot of the network compensation penalty versus the value
of the strongly constrained network parameter, for networks that are both inducible and dosage invariant.
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topologies its values are tightly distributed around 1
(Figure 3A and B). Plotting the penalty to compensa-
tion against the strongly constrained parameter further
confirms that having the value of the parameter to be
very close to 1 is necessary for a small compensation
penalty in an inducible network (Figure 3C and D).
Sufficiency analysis of the network-dosage compensation
conditions for well-behaved gene networks
The analysis above shows that having one of the two
network topologies shown in Figure 1B and C, as well as
a 1:1 stoichiometric interaction between the activator
and the inhibitor, are necessary conditions for a network
to be both inducible and dosage-compensated. The
question remains, however, whether these conditions are
sufficient for an inducible network to be network-dosage
compensated. To answer this question, we examined the
compensation penalty of all networks whose constrained
parameter (α or β) is in the range [0.9, 1.1], and whose
inducibility penalty is below 0.10.
As shown in Figure 4B, of the examined networks with
the topology in Figure 1C, 97.6% have a compensation
penalty below 0.10, and 99.3% have a compensation pen-
alty below 0.15. However, approximately 28.3% of the ex-
amined networks with the topology in Figure 1B have
compensation penalties above 0.10, with 23% above 0.15(Figure 4A), necessitating a more detailed examination
of those networks.
Further examining those networks, we found that the
networks with high compensation penalties uniformly
have very small values of Si, the parameter representing
the strength of the inhibitor (Figure 4C). Moreover, the
maximum inhibitory effect achievable in such systems is
very small (Figure 4D) compared to those in compensated
systems (Figure 4E). In short, the inhibitory component of
these networks is very weak, such that 1 + (Sii)
β ≈ 1 and
the networks become essentially 1-component networks
with a single direct activator. Such networks can still be
fully inducible, but they cannot be dosage compensated
[10]. Moreover, an inhibitor with so weak an inhibitory
effect is unlikely to play any significant part in the output
of any naturally occurring gene network.
We define a well-behaved gene network as a gene network
that satisfies the following two conditions: 1) the network is
inducible and 2) the activating or inhibiting effect of each
network component on overall network output is sub-
stantial, i.e., where the approximations 1 + (Sii)
β ≈ 1 and
1 + (Saa)
α ≈ 1 do not hold. The above analysis supports the
conclusion that for a well-behaved 2-component subnet-
work to show dosage compensation, it is sufficient that
the subnetwork has a topology shown in Figure 1B or C,
and that the stoichiometry between the activator and the
inhibitor is 1:1. As naturally occurring gene regulatory
Figure 4 Sufficiency analysis of the network-dosage compensation conditions. A-B. Histogram of compensation penalty of networks with
inducibility penalty < = 0.1 and constrained parameter value between 0.9 and 1.1, for the topology shown in Figure 1B (A) and Figure 1C (B).
C. Values of Si for networks in part A with compensation penalty > 0.1. D. Maximum steady state repression in networks with high compensation
penalties. Value of 1 means no repression; smaller value means stronger repression. E. Maximum steady state repression in dosage
compensated networks.
Song et al. BMC Systems Biology 2014, 8:69 Page 7 of 11
http://www.biomedcentral.com/1752-0509/8/69networks are very likely to be well-behaved, if a natural
gene network satisfies these two requirements, it would be
expected to be network-dosage compensated.
Recurrent nature of the dosage-compensation motifs in
the Saccharomyces cerevisiae genome
To find out how frequently the dosage compensation
structures occur in the yeast genome, we examined a set
of 1,385 genes that have regulatory roles in S. cerevisiae,
and 166 transcription factors (TF) that, in turn, regulate
their transcription (Figure 5 and Additional files 2, 3). We
limited our search to regulators because our dosage com-
pensation structure requires both network components to
affect their own transcription, directly or indirectly.
Since the network components in our dosage com-
pensation structures are expected to affect the activity
of the TF, they should physically interact with the TF
either directly or indirectly. Moreover, since they are
regulatory components of this network, they should gen-
etically interact with each other, and with the TF. There-
fore, we defined a potentially compensated unit (PCU) to
be composed of two regulators and a TF that binds to the
promoter of both of them, and in which 1) at least one
regulator has a physical interaction with the TF, 2) each
regulator has a reported physical interaction with either
the TF or the other regulator, 3) the two regulators have at
least one reported genetic interaction, and 4) at least one
regulator has a reported genetic interaction with the TF.
Using this definition, we enumerated all possible PCUs
using TF-DNA binding and physical and genetic interactiondata (Methods, Figure 5). PCUs whose components in-
volve global regulators, which does not regulate a small
set of genes or process, were excluded. This resulted in
a list of 82 PCUs, involving 57 unique regulators and 23
unique TFs (one regulator can be part of many PCUs)
(Additional file 4).
We then determined if the two regulators in each PCU
have different regulatory signs, as required by the dosage
compensation structure. Since the network structure
requires the regulators to be co-expressed, we are not
able to use gene expression data. Instead, we examined
the documented genetic interactions between the two
regulators. If the genetic interaction suggests that one
regulator could compensate for the deletion of the
other, we interpreted this as their having the same
regulatory sign; conversely, if deletion of one regulator
could compensate for the deletion of the other, then
the two regulators would have different regulatory signs.
Further, we looked at the physical interactions in each PCU
to ensure that only one regulator physically interacts with
the TF, as required by the topologies (Figure 1B-C).
In many cases, a regulator was part of multiple PCUs,
some compensated and others non-compensated, because
we enumerated all possible combinations. In addition,
we observed several instances of false positives in PCUs
reported to be potentially compensated. To get a more
accurate picture of the prevalence of dosage compensa-
tion structures, we manually combined the 82 PCUs
into 15 larger networks (Table 2) and verified the dosage
compensation structure against the literature to ensure
Transcription regulators  
(possible network elements) 
Transcription factor (TF) 
binding data 
Pairs of transcription regulators whose 
promoters are bound by the same TF 
TF-regulator pair combinations that are 
linked by physical interactions 
Remove combinations in which the 
regulators have no genetic interaction with 
each other or no genetic interaction with the 
TF 
Genetic interaction  
data 
Merge combinations into larger networks 
and count networks with dosage 
compensation structures 
Protein physical  
interaction data 
Figure 5 Overview of the algorithm employed to search in the yeast genome for the abundance of the special topologies necessary
for network-dosage compensation. The algorithm takes as input a set of precompiled possible network elements (genes that potentially have
a role in transcription regulation within each network), transcription factor binding data for the promoter region of each element, and physical
and genetic interaction data among the elements and the transcription factors. The algorithm first searches for all possible two-component
networks in which both elements are under the control of the same TF, and could influence their own expression by interacting with that TF
directly or indirectly. Then, using the genetic interaction data, it attempts to determine whether the two components are of different regulatory
signs and then reach a definitive conclusion on the presence of a dosage compensation motif for each TF-network combination based on the
topology of the physical interaction and the regulatory sign. In post-processing, combinations for which a definitive conclusion can be made are
manually combined into larger networks and the dosage compensated structures in each are counted.
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15 networks, we found that 5 networks have at least one
verified dosage compensation structure (Figure 6). One of
the five we found is the GAL network [10], while the
others were related to pheromone response [11], response
to osmotic stress [12], cell cycle control [13], and nitrogen
catabolite repression [14], respectively.
We then checked if those 5 networks satisfied the
stoichiometry requirement. For the GAL network, the
Gal3p-Gal80p interaction was reported in the litera-
ture to be of 1:1 stoichiometry [20]. For the networks
regulating pheromone response [11], and response to
osmotic stress [12], we found evidence that both
Gpa1p and Ptp3p has only one known MAPK-binding
motif, whose mutation abolished MAPK binding
[21,22], and mutations in a single amino acid residue
in Fus3p and Hog1p were sufficient to abolish their
binding to Ptp3p [12,21], indicating that they have onlyone binding site each for the MAPK-binding motif.
Similarly, for the cell-cycle control network [13], muta-
tion of two amino acid residues close together were
sufficient to abolish Clb2p-Swe1p binding, suggesting
that Clb2p only has a single binding site for Swe1p [17].
Finally, for the network regulating nitrogen catabolite re-
pression [14], we found that, although Ure2p exists as a
dimer in solution [23,24], Gln3p has only one domain that
interacts with Ure2p [25].
Discussion
Although dosage compensation characteristics of individual
genes have received some attention over the years [7-9], we
are not aware of any studies into the dosage compensation
characteristics of entire gene networks, with the exception
of the previous work [10] carried out by one of the authors
of this manuscript. It is worth emphasizing that changes in
gene dosage, whether by loss of a single copy of the gene,
Table 2 List of the 15 larger networks resulting from
merging the PCUs
Network Genes and TFs References
1 STE12, FUS3, GPA1, KSS1, DIG1, SST2, FAR1 [11,15]
2 SKO1, PTP3, HOG1, MSN2, WHI2, RCK2 [12,16]
3 GAL4, GAL3, GAL80, GAL1 [10]
4 SWI4, SWE1, CLB2, SWI6, CDC6 [13,17]
5 GCN4, GLN3, URE2 [14,18,19]
6 RAP1, TEL1, RIF2
7 INO4, INO2, TYE7
8 INO4, INO2, OPI1
9 SKN7, YAP1, TRR1, TRX2
10 PHO4, CLN3, PHO85, CRZ1
11 AFT1, SIT1
12 IME1, IME2
13 CBF4, MET4, MET30, MET32
14 MIG1, HXK2
15 RPN4, RPT2, RPT6, RPT3, RPT5, RPT1,
SEM1, UBP6
Networks 1–5 have at least one dosage compensation structure satisfying all
topological constraints. For these networks, the transcription factor involved in
the structure is bolded, the two network components in that structure are
italicized and references documenting the interactions among those
components and the TF are listed in the rightmost column. If a network
contains more than one such structure, only one is shown.
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as those that frequently occur in cancerous cells [26], typ-
ically result in changes in the dosage of some, but not all,
genes in a gene network, to which network-dosage com-
pensation does not apply. We expect changes in the effect-
ive dosage of entire gene networks to typically arise from
far more mundane situations such as normal cell growth,
global transcriptional variations, and other normal bio-
logical processes, but the very mundaneness of these
situations is strongly indicative of the need for cells to
be able to compensate for network-dosage changes. Thus,
while it is perhaps unsurprising that most of the yeast genes
are not compensated with respect to single gene dosage
changes [8], our results here show that several gene net-
works with diverse biological functions carry the structure
necessary for network-dosage compensation.
It should be noted that, while not all natural networks
are expected to display the compensation requirements,
our results are highly likely to underrepresent the actual
number of natural networks satisfying such requirements.
This is because, in cases where the “direct” activator or in-
hibitor in the network actually affects its own transcription
via some intermediary protein, the network may well have
the dosage compensation topology, but our method would
not be able to detect them. In addition, our classification of
genes into activators and inhibitors, necessary to detect the
required network topology, is based on genetic interactiondata and hence is necessarily limited by the availability
of such data. In particular, as large-scale genetic inter-
action studies are frequently reliant on generation of
double mutants [27], genetic interaction data are of
relatively limited assistance with interactions among
essential transcription regulators whose mutations can
be lethal. Yet, those essential transcription regulators
are likely the ones most in need of dosage compensation
mechanisms. Thus, we believe that in reality the number
of gene networks carrying the dosage compensation top-
ology would likely be significantly larger.
Conclusions
In summary, our work provides the most general network-
dosage compensation analysis to date, expanding the ana-
lysis from 2-component gene networks to N-component
networks. Here we show that the network-dosage compen-
sation mechanism is not restricted to network components
with specific gene expression and protein degradation
levels, but the mechanism can robustly operate over large
ranges. Furthermore, we show that the conditions that are
necessary for an inducible network to be dosage compen-
sated are also sufficient. Finally, using genome-wide binding
and gene expression datasets, here we demonstrate the
recurrent nature of the special topologies or motifs
needed for network-dosage compensation. As a result
of identifying and merging 82 compensation units
(Additional file 4) in yeast, we obtained 15 larger networks
(Table 2). Out of these 15 large networks, we were able to
find evidence in the literature that 5 of them (33%) carried
the dosage compensation requirements identified in our
work (specific topologies and stoichiometry). This number,
as we explain above, is likely to significantly underrepresent
the actual number of dosage-compensated networks.
The dosage compensation motifs we analyzed show
strong similarity to the sequestration-based regulatory net-
works [10,12]. Sequestration-based mechanisms are widely
present in eukaryotic organisms, and regulate a wide variety
of biological processes [28,29]. Dosage compensation is
expected to be advantageous during natural selection. The
widespread occurrence of sequestration-based mechanisms
lends further support to the conclusion that network dos-
age compensation can be an important component of na-
ture’s design for gene network architecture in cells.
Methods
Sampling of network parameters
All possible combinations of the parameters θa, θi, ta, ti
(144 in total, see Table 1) were tested for each network
topology. For each combination of those four parameters
and network topology, 10,000 sets of values for the param-
eters Sa, Si, α and β were sampled from the corresponding
distribution specified in Table 1, for a total of 1,440,000
networks examined per topology.
Figure 6 Illustration of networks 1–5 in Table 2. A network-dosage compensation motif in each network (the same motif noted in Table 2) is
highlighted using bolded font and borders. If a network contains more than one such motif, only one is highlighted.
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http://www.biomedcentral.com/1752-0509/8/69Production of numerical inducibility curves
Each network is numerically integrated from t = 0 to
t = 24 h for each possible value of g specified in the
table. The starting state is assumed to be the steady
state at basal transcription levels, i.e., a ¼ θaλaγ0þγa ; i ¼
θiλi
γ0þγ i .
The value of f(a,i,g) at t = 24 h was calculated. A small
percentage of the networks sampled displayed numer-
ical problems during integration and were excluded
from further analysis.
Transcription regulators and transcription factor binding
We generated a list of all verified yeast ORFs annotated
with the GO term “biological regulation” (GO:0065007)
or one of its children using the Saccharomyces Genome
Database [30]. For each regulator in the list, we obtained
a list of transcription factors that bind to the promoter
from the YEASTRACT database [31-33], limiting our
search to documented evidence of TF binding to pro-
moter. We also added regulator binding data from
MacIssac et al., using moderate binding constraints and
strong conservation constraints [34]. The original lists
of regulators and transcription factors are provided in
Additional files 2 and 3.
Physical interactions
Physical and genetic interaction data for all genes in-
volved were obtained from BioGRID [35]. To reduce
false positives in physical interactions, we required
two proteins to have either one reported low-throughput
physical interaction or two reported high-throughput
physical interactions in the database to be considered phys-
ically interacting.Classification of genetic interactions
Genetic interactions are classified into positive interactions
and negative interactions. Positive interactions represent
cases where the double mutant has a less severe phenotype
than either single mutant, which indicates that the two net-
work components should have different regulatory signs.
Such interactions are classified in BioGRID as synthetic
rescue, positive genetic, dosage growth defect, or dosage
lethality. Conversely, negative interactions represent cases
where a double mutant has a more severe phenotype than
expected, and indicate that the two components in the gene
network should complement each other, and therefore have
the same regulatory sign. Such interactions are classified in
BioGRID as dosage rescue, negative genetic, synthetic growth
defect, synthetic lethality, or synthetic haploinsufficiency.
If the above system causes the overall interaction
between two genes to be classified as both positive and
negative, or if the only genetic interactions reported in
BioGRID are classified as phenotypic enhancement and
phenotypic suppression (the definitions of these terms
are too broad to permit the simple classification above),
then the interaction is manually classified based on the
publications documenting the interaction.
Availability of supporting data
The data sets supporting the results of this article are
included within the article and its additional files.
Additional files
Additional file 1: This file contains supplementary Figures S1-S3.
Additional file 2: List of the 1385 yeast regulators examined.
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http://www.biomedcentral.com/1752-0509/8/69Additional file 3: List of the 166 transcription factors that bind to
the promoter of the yeast regulators examined.
Additional file 4: List of the 82 PCUs. PCUs whose structures were
verified to be consistent with dosage compensation are bolded.
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